MARKET

UTHR

UTHR

United Therapeutics Corp.
NASDAQ
503.86
-2.96
-0.58%
Closed 19:30 09/10 EDT
OPEN
502.44
PREV CLOSE
506.82
HIGH
509.79
LOW
497.91
VOLUME
653.16K
TURNOVER
0
52 WEEK HIGH
609.35
52 WEEK LOW
388.73
MARKET CAP
21.61B
P/E (TTM)
18.02
1D
5D
1M
3M
1Y
5Y
1D
Is United Therapeutics (UTHR) A Bargain Following Its Tyvaso FDA Acceptance?
Simply Wall St · 1d ago
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), United Therapeutics (UTHR) and Spyre Therapeutics (SYRE)
TipRanks · 2d ago
United Therapeutics Announces New Accelerated Share Repurchase
TipRanks · 2d ago
United Therapeutics enters $477.6M accelerated share repurchase
Seeking Alpha · 3d ago
United Therapeutics announces accelerated share repurchase agreement
TipRanks · 3d ago
*United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement For Remainder Of $2.0 Billion Authorization >UTHR
Dow Jones · 3d ago
Weekly Report: what happened at UTHR last week (0831-0904)?
Weekly Report · 4d ago
United Therapeutics (UTHR) Stock May Be Undervalued Despite Its 132% Run
Simply Wall St · 6d ago
More
About UTHR
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia.

Webull offers United Therapeutics Corp stock information, including NASDAQ: UTHR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UTHR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading UTHR stock methods without spending real money on the virtual paper trading platform.